Nature Communications

Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006)

2025-12-08

Full text

DOI https://doi.org/10.1038/s41467-025-66342-2